Urologix Stock Price, News & Analysis (OTCMKTS:ULGX)

$0.0023 0.00 (0.00 %)
(As of 12/14/2017 03:31 PM ET)
Previous Close$0.00
Today's Range$0.00 - $0.00
52-Week RangeN/A
Volume181,930 shs
Average Volume8,678 shs
Market Capitalization$20,000.00
P/E RatioN/A
Dividend YieldN/A
Beta5.52

About Urologix (OTCMKTS:ULGX)

21st North Inc., formerly Urologix Inc., was engaged in developing, manufacturing, marketing and distributing medical products. The Company offered its products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The Company has no operations. The Company intends to dissolve.

Receive ULGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ULGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ULGX
CUSIPN/A
Phone612-475-1400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares21,820,000

Urologix (OTCMKTS:ULGX) Frequently Asked Questions

What is Urologix's stock symbol?

Urologix trades on the OTCMKTS under the ticker symbol "ULGX."

How were Urologix's earnings last quarter?

Urologix Inc. (OTCMKTS:ULGX) issued its earnings results on Thursday, February, 5th. The company reported ($0.02) EPS for the quarter. The business earned $3.10 million during the quarter, compared to the consensus estimate of $3.80 million. View Urologix's Earnings History.

Who are some of Urologix's key competitors?

Who are Urologix's key executives?

Urologix's management team includes the folowing people:

  • Gregory J. Fluet, Chief Executive Officer, Director (Age 45)
  • Scott M Madson, Chief Financial Officer (Age 51)
  • Lisa A. Ackermann, Executive Vice President - Sales and Marketing (Age 42)
  • Mitchell Dann, Independent Non-Executive Chairman of the Board, Lead Director (Age 54)
  • Christopher R. Barys, Independent Director (Age 48)
  • Sidney W. Emery Jr., Independent Director (Age 70)
  • Patrick D. Spangler, Independent Director (Age 59)

How do I buy Urologix stock?

Shares of Urologix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Urologix's stock price today?

One share of Urologix stock can currently be purchased for approximately $0.00.

How big of a company is Urologix?

Urologix has a market capitalization of $20,000.00.

How can I contact Urologix?

Urologix's mailing address is 14405 21ST AVE N, MINNEAPOLIS MN, 55447. The company can be reached via phone at 612-475-1400 or via email at [email protected]


MarketBeat Community Rating for Urologix (ULGX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  16 (Vote Outperform)
Underperform Votes:  14 (Vote Underperform)
Total Votes:  30
MarketBeat's community ratings are surveys of what our community members think about Urologix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Urologix (OTCMKTS:ULGX) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Urologix (OTCMKTS:ULGX) Earnings History and Estimates Chart

Earnings by Quarter for Urologix (OTCMKTS:ULGX)

Urologix (OTCMKTS ULGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2015Q215($0.02)$3.80 million$3.10 millionViewListenView Earnings Details
8/19/2014Q4 14($0.17)$3.29 millionViewN/AView Earnings Details
2/4/2014Q4($0.05)$3.81 millionViewListenView Earnings Details
11/14/2012Q113($0.06)($0.05)$4.48 million$4.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Urologix (OTCMKTS:ULGX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Urologix (OTCMKTS:ULGX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Urologix (OTCMKTS ULGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.50%
Institutional Ownership Percentage: 0.28%
Insider Trades by Quarter for Urologix (OTCMKTS:ULGX)

Urologix (OTCMKTS ULGX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/26/2013Gregory FluetCEOBuy17,500$0.31$5,425.00View SEC Filing  
7/12/2013Mitchell DannDirectorBuy20,000$0.30$6,000.00View SEC Filing  
7/10/2013Gregory FluetCEOBuy25,000$0.24$6,000.00View SEC Filing  
7/9/2013Lisa A AckermannEVPBuy18,500$0.24$4,440.00View SEC Filing  
7/8/2013Gregory FluetCEOBuy66,400$0.19$12,616.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Urologix (OTCMKTS ULGX) News Headlines

Source:

SEC Filings

Urologix (OTCMKTS:ULGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Urologix (OTCMKTS:ULGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Urologix (OTCMKTS ULGX) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.